Predilife S.A.

Paris Stock Exchange ALPRE.PA

Predilife S.A. Capital Expenditure for the year ending December 31, 2023: USD -46.84 K

Predilife S.A. Capital Expenditure is USD -46.84 K for the year ending December 31, 2023, a -62.17% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Predilife S.A. Capital Expenditure for the year ending December 31, 2022 was USD -28.88 K, a -652.59% change year over year.
Predilife S.A. Capital Expenditure for the year ending December 31, 2021 was USD -3.84 K, a 79.97% change year over year.
Predilife S.A. Capital Expenditure for the year ending December 31, 2020 was USD -19.16 K, a 21.70% change year over year.
Predilife S.A. Capital Expenditure for the year ending December 31, 2019 was USD -24.47 K, a 88.63% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: ALPRE.PA

Predilife S.A.

CEO	Mr. Stephane Ragusa
IPO Date	Dec. 21, 2018
Location	France
Headquarters	39, Rue Camille Desmoulins
Employees	18
Sector	Consumers Staples
Industries Personal Care 3D Printing Biotechnology Clinical Trials Cosmetics Dental Care Medical Instruments Pharmaceuticals

Description

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Key trends

Past 5 years